Is tesamorelin FDA-approved?

Yes — uniquely among GHRH analogues, tesamorelin (Egrifta) is FDA-approved for one specific indication: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. It is the only drug approved for this condition. It is not approved for body composition improvement, anti-aging, cognitive enhancement, or any other purpose, and it is prohibited in competitive sport by WADA.

How is tesamorelin dosed in the approved indication?

The FDA-approved dose is 2 mg subcutaneously once daily, injected into the abdomen. Benefits require continuous administration — visceral fat returns to baseline within approximately 26 weeks of stopping. IGF-1 and fasting glucose monitoring are recommended during treatment.

How does tesamorelin differ from other GHRH analogues like sermorelin or CJC-1295?

Tesamorelin is the full 44-amino acid GHRH sequence with a DPP-IV-blocking N-terminal modification, the only FDA-approved GHRH analogue, and the only one with large Phase 3 trial data. Sermorelin is a shorter 29-amino acid fragment with no current drug approval. CJC-1295 with DAC uses a different mechanism (covalent albumin binding) to produce sustained tonic GH elevation — a non-physiological profile distinct from tesamorelin's pulsatile GH release — and has no published clinical trial efficacy data.

Can tesamorelin improve cognition or liver fat?

Small randomised trials suggest possible benefits: a 152-person RCT found improvements in executive function and overall cognition at 20 weeks, and two RCTs found reduced hepatic fat in HIV patients with NAFLD. These findings are preliminary and not replicated sufficiently for regulatory approval; tesamorelin is not approved for cognitive or liver disease indications.

What are the main safety risks?

The main concerns are: (1) glucose: new-onset diabetes in ~5% vs. 1% placebo in trials (HR ~3.3), requiring monitoring; (2) elevated IGF-1, which is theoretically mitogenic; (3) contraindication in active malignancy, pituitary disease, and pregnancy. Injection-site reactions and arthralgia are the most common adverse events. Long-term cancer risk is unresolved but was not statistically significant in Phase 3 data.

Does tesamorelin work for body composition in people without HIV?

One small RCT in non-HIV obese adults with relative GH deficiency showed significant visceral fat and triglyceride reduction, suggesting effects may not be unique to HIV. However, this study was small, the benefit was seen primarily in those with documented blunted GH secretion, and tesamorelin is not approved or indicated for non-HIV obesity.

Hormonal

Tesamorelin

Also known as: TH9507, Egrifta, Egrifta SV, Egrifta WR, trans-3-hexenoic acid-GHRH(1-44)

A synthetic GHRH analogue that is FDA-approved for HIV-associated lipodystrophy; studied in research settings for visceral fat reduction, hepatic steatosis, and cognitive...

Last updated July 11, 2026

Buy Tesamorelin

Overview

Tesamorelin is a 44-amino acid synthetic analogue of endogenous growth hormone-releasing hormone (GHRH) in which the N-terminal tyrosine carries a covalently attached trans-3-hexenoic acid group. This modification shields the peptide from dipeptidyl peptidase IV (DPP-IV) cleavage, extending its functional half-life compared to native GHRH while preserving the ability to bind and activate the pituitary GHRH receptor. Tesamorelin is the first and, as of 2026, only FDA-approved pharmacological treatment for HIV-associated lipodystrophy — specifically the excess visceral abdominal fat accumulation seen in HIV-infected adults on antiretroviral therapy. It was approved in 2010 under the brand name Egrifta (NDA 022505), with subsequent formulations Egrifta SV (2019) and Egrifta WR (2025) improving convenience. The EMA did not grant European approval; a marketing application was withdrawn in 2011. Beyond its approved indication, tesamorelin has been studied in small randomized trials for HIV-associated non-alcoholic fatty liver disease (NAFLD), cognitive function in older adults and those with mild cognitive impairment, and visceral fat reduction in non-HIV obese adults with relative growth hormone deficiency. These applications remain investigational. As a growth hormone secretagogue, tesamorelin produces pulsatile GH release — considered more physiological than exogenous recombinant GH administration — and subsequently raises IGF-1. It is prohibited in competitive sport by WADA (S2 category). Outside its single FDA-approved indication, tesamorelin is available only for research use and is not validated for other human therapeutic applications.

How it works

Tesamorelin binds the GHRH receptor (GHRH-R), a class B secretin-family GPCR expressed on anterior pituitary somatotroph cells. Receptor engagement activates Gs-coupled adenylyl cyclase, raising intracellular cAMP and activating PKA, which phosphorylates CREB and drives GH gene transcription via the Pit-1 transcription factor. Simultaneously, voltage-gated calcium channel activation triggers exocytosis of GH-containing secretory granules. The result is pulsatile, physiologically patterned GH release rather than the tonically elevated GH seen with direct recombinant GH administration. Released GH acts on hepatic GH receptors via JAK2-STAT5 signaling to stimulate IGF-1 production, which in turn promotes lipolysis in visceral adipose tissue, lean mass anabolism, and provides negative feedback to the hypothalamus and pituitary. The trans-3-hexenoic acid N-terminal modification blocks DPP-IV cleavage at the His2-Ala3 bond that rapidly inactivates native GHRH, extending systemic functional duration without altering receptor binding geometry. These mechanisms are well established in both preclinical models and human clinical pharmacology studies.

Researched effects

Clinical Reduces visceral adipose tissue (VAT) by ~15–20% in HIV-positive adults with lipodystrophy
Clinical Reduces triglycerides and improves waist circumference in HIV lipodystrophy
Clinical Reduces hepatic fat fraction in HIV-associated NAFLD
Clinical Improves executive function and overall cognition in older adults with and without mild cognitive impairment
Clinical Reduces visceral fat in non-HIV adults with central obesity and relative GH deficiency
Clinical Improves body image and appearance-related distress in HIV lipodystrophy patients
Clinical Increases lean body mass modestly in the context of lipodystrophy treatment

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

FDA-approved dose: 2 mg subcutaneously once daily (abdomen), administered as Egrifta, Egrifta SV, or Egrifta WR. This is specifically approved for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Benefits reverse within 26 weeks of discontinuation; continuous daily administration is required to maintain VAT reduction. Monitoring of IGF-1 levels and fasting glucose is recommended; discontinuation should be considered if IGF-1 SDS consistently exceeds +2. In research studies outside the approved indication (cognition, NAFLD), doses of 1–2 mg/day SC have been used. No other indication carries regulatory approval.

Community-reported dosing (anecdotal)

Anecdotal and research-reference only; not medical advice or instruction. Outside the HIV lipodystrophy context, anecdotal community use (as documented on research forums and peptide discussion communities) mirrors the clinical dose of 1–2 mg SC once daily. Some community protocols describe cycling at 1 mg/day with periodic breaks, primarily targeting visceral fat or anti-aging goals. These uses are unapproved, unstudied outside controlled research, and carry all the risks of unregulated peptide sourcing.

Half-life: Short, with a pharmacokinetically important distinction between single-dose and steady-state values. In healthy subjects, single-dose plasma half-life is approximately 8 minutes; in HIV-positive patients it is approximately 18.6 minutes; at steady state (14 days of daily dosing) approximately 37.8 minutes. These figures reflect plasma drug exposure, which is distinct from the biological duration of pulsatile GH release. Absolute subcutaneous bioavailability is less than 4%.
Routes: subcutaneous

Safety & side effects

Tesamorelin carries a well-characterised safety profile from Phase 3 trials (n=816) and post-marketing experience. Common adverse events include injection-site reactions (24–32% vs. 12–18% placebo, mostly Grade 1 and self-resolving), arthralgia (13–15%), and peripheral edema (6–11%). A meaningful glucose signal was observed: new-onset diabetes occurred in 5% vs. 1% of placebo patients (HR ~3.3, 95% CI 1.4–9.6), though HOMA-IR was not significantly worsened long-term; fasting glucose monitoring is recommended. Anti-drug antibodies develop in approximately 50% of patients at 26 weeks but have not been shown to reduce efficacy or cause immune-mediated harm. IGF-1 levels exceeded +2 SDS in 47% of patients at 26 weeks; sustained supraphysiological IGF-1 is theoretically mitogenic, and 8 vs. 3 malignancies were observed in the Phase 3 pooled population (p=0.18, not statistically significant, but data are limited). Contraindications include: active or suspected malignancy; disrupted hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumors, cranial irradiation); pregnancy (GHRH analogues are Pregnancy Category X); hypersensitivity to tesamorelin or mannitol. VAT benefits reverse fully within approximately 26 weeks of stopping treatment. Tesamorelin is prohibited in competitive sport under WADA category S2 (peptide hormones, growth factors, related substances). Outside its approved HIV lipodystrophy indication it is a research compound only and is not FDA-approved for anti-aging, body composition, or cognitive applications.

Research summary

Tesamorelin has the most robust human evidence base of any GHRH analogue. Two independent Phase 3 randomised placebo-controlled trials (LIPO-010 and CTR-1011, combined n=816) demonstrated statistically and clinically significant reductions in visceral adipose tissue at 26 weeks (-15 to -20% net reduction in VAT area by CT, p<0.001) in HIV-infected adults with lipodystrophy. Secondary endpoints including triglycerides, waist circumference, and patient-reported belly appearance were also improved. VAT returns to baseline within ~26 weeks of stopping, limiting the intervention to continuous use. Beyond lipodystrophy, two RCTs have demonstrated hepatic fat reduction in HIV-associated NAFLD (Stanley et al., JAMA 2014, and a 2019 Lancet HIV trial), and a single 152-participant RCT (Baker et al., Arch Neurol 2012) found significant improvements in executive function and overall cognition in older adults at 20 weeks, though this has not been independently replicated. A smaller trial in non-HIV obese adults with relative GH deficiency (Makimura et al., JCEM 2012) showed significant VAT and triglyceride reduction, suggesting effects may generalise beyond HIV. The glucose safety signal — particularly the new-onset diabetes hazard ratio of ~3.3 — warrants clinical caution and monitoring. The malignancy question (8 vs. 3 events in pooled Phase 3) is not resolved but was not statistically significant. Anti-drug antibodies in ~50% of patients do not appear to attenuate efficacy. Long-term (>2 year) safety data remain limited. Overall, tesamorelin is the best-evidenced GHRH analogue by far, with genuine Phase 3 trial support for its approved indication. Off-label applications (cognition, non-HIV obesity, NAFLD) are supported by smaller trials but have not achieved regulatory approval and should be regarded as promising but unproven.

FAQ

Is tesamorelin FDA-approved?: Yes — uniquely among GHRH analogues, tesamorelin (Egrifta) is FDA-approved for one specific indication: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. It is the only drug approved for this condition. It is not approved for body composition improvement, anti-aging, cognitive enhancement, or any other purpose, and it is prohibited in competitive sport by WADA.
How is tesamorelin dosed in the approved indication?: The FDA-approved dose is 2 mg subcutaneously once daily, injected into the abdomen. Benefits require continuous administration — visceral fat returns to baseline within approximately 26 weeks of stopping. IGF-1 and fasting glucose monitoring are recommended during treatment.
How does tesamorelin differ from other GHRH analogues like sermorelin or CJC-1295?: Tesamorelin is the full 44-amino acid GHRH sequence with a DPP-IV-blocking N-terminal modification, the only FDA-approved GHRH analogue, and the only one with large Phase 3 trial data. Sermorelin is a shorter 29-amino acid fragment with no current drug approval. CJC-1295 with DAC uses a different mechanism (covalent albumin binding) to produce sustained tonic GH elevation — a non-physiological profile distinct from tesamorelin's pulsatile GH release — and has no published clinical trial efficacy data.
Can tesamorelin improve cognition or liver fat?: Small randomised trials suggest possible benefits: a 152-person RCT found improvements in executive function and overall cognition at 20 weeks, and two RCTs found reduced hepatic fat in HIV patients with NAFLD. These findings are preliminary and not replicated sufficiently for regulatory approval; tesamorelin is not approved for cognitive or liver disease indications.
What are the main safety risks?: The main concerns are: (1) glucose: new-onset diabetes in ~5% vs. 1% placebo in trials (HR ~3.3), requiring monitoring; (2) elevated IGF-1, which is theoretically mitogenic; (3) contraindication in active malignancy, pituitary disease, and pregnancy. Injection-site reactions and arthralgia are the most common adverse events. Long-term cancer risk is unresolved but was not statistically significant in Phase 3 data.
Does tesamorelin work for body composition in people without HIV?: One small RCT in non-HIV obese adults with relative GH deficiency showed significant visceral fat and triglyceride reduction, suggesting effects may not be unique to HIV. However, this study was small, the benefit was seen primarily in those with documented blunted GH secretion, and tesamorelin is not approved or indicated for non-HIV obesity.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.